Bavarian Nordic Seeks Partner After RSV Jab Generates Glowing Phase II Data
Danish Biotech CEO Says Commercializing MVA-BN RSV Is Key Objective Now
Executive Summary
Solid Phase II data for Bavarian Nordic’s investigational vaccine MVA-BN RSV showed falls in both symptoms and viral load of respiratory syncytial virus in the challenge trial’s adult participants, boosting prospects for a Phase III trial - and for finding a commercial partner.
You may also be interested in...
Bavarian Nordic To Raise $250m For Phase III RSV Vaccine Study
The firm anticipates a late-stage study of MVA-BN RSV in the first half of 2022
J&J Sets The Pace In Race To $10bn RSV Vaccine Market
Johnson & Johnson has impressed with its Phase II data but Pfizer and GSK have both already begun their Phase III studies.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.